WW announced that it will be offering compounded semaglutide to members of WW Clinic, charging $189 a month for the medication, or $129 for the first month if members sign up for a longer-term commitment plan, Craig-Hallum analyst Alex Fuhrman tells investors in a research note. While the firm is optimistic about WW’s launch of a compounded semaglutide offering that will allow the brand to compete on an even footing for the upcoming post New Year’s Diet Season and sees the potential for the stock to work, Craig-Hallum keeps a Hold rating in part because consensus estimates for next year are still too high.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WW:
- Barclays does not view compounding as durable business model for WeightWatchers
- PepsiCo reports mixed Q3, Roblox slips after short report: Morning Buzz
- WeightWatchers jumps after adding compounded weight loss drugs
- WW adds compounded GLP-1, expanding accessibility og weight loss medications
- Costco reports Q4 earnings beat, Cassava to settle SEC charges: Morning Buzz